Have you passed the non-invasive procedure? Should I send you a message first?

Is it necessary to send information first after the non-invasive test is completed?

Should the information be sent first after the non-invasive test is completed? It can be said that pregnant women need it every month during the ten months of pregnancy. Go to the hospital for a prenatal check-up, and the non-invasive DNA test is a test that every pregnant woman will do. So, should you send information first if you have passed the non-invasive test? Should I send you the information first if you have passed the non-invasive test? 1

The test results are usually available within about five days. The way most hospitals deal with this is to send notification messages. If there are any abnormalities, we will call you to inform you. Then get the test results. It usually takes half a month for inspection results to be available. It is recommended to do various pregnancy check-ups.

What does it mean for pregnant women to undergo non-invasive DNA testing?

Pregnant women undergoing non-invasive DNA testing is an option in the prenatal check-up program. Not every pregnant woman needs to undergo non-invasive testing. Non-invasive prenatal testing is mainly In order to check whether the fetal DNA is normal, you can check whether the fetus has genetic diseases. There are three common chromosomal diseases.

Among the prenatal check-up items, the test that pregnant women will definitely do is Down’s syndrome screening. According to the results of Down’s syndrome screening, if it is low-risk, there is no need for non-invasive tests. The result is high risk. In order to make a more accurate diagnosis, pregnant women will generally continue to undergo non-invasive procedures. If the non-invasive results are normal, it means that the risk of the fetus having chromosomal diseases is very small, and the pregnant women can continue the pregnancy.

What are the benefits of non-invasive testing for pregnant women?

1. Non-invasive: Non-invasive DNA testing only requires 5 ml of blood to be extracted from the body of pregnant women. Relevant DNA can be extracted from part of the blood, so that relevant examinations and techniques can be used in the laboratory to analyze the free DNA fragments to determine whether the current fetus has chromosomes 13, 18, and 21 and whether there are abnormalities. Therefore, it is non-invasive and safer for pregnant women. And the accuracy of these three chromosome tests can reach 99%.

2. Safe and no risk of infection: Traditional Down syndrome screening, or amniocentesis and other interventional diagnostic methods may cause infection of the fetus in the body during the examination. Amniotic fluid puncture is required If not performed properly, it will damage the fetus and the uterus of the pregnant woman, and even cause miscarriage. Non-invasive prenatal genetic testing can more effectively ensure the safety of pregnant women and fetuses.

3. Check the gestational age early and the detection time is short: Regarding the time of examination, the time for maternal abnormality examination is within the 13th to 22nd week of pregnancy. If the amniocentesis test is performed, Results can take 3 to 4 weeks, but with non-invasive prenatal genetic testing, detailed test results can be obtained in just 10 working days.

After the above introduction, people already know that the main purpose of non-invasive examination for pregnant women is to check whether the fetus has chromosomal diseases. If such examination is not done and a fetus with problems is born, it will bring great consequences to the whole family. A lot of pressure. It is difficult for children with Down syndrome to have the ability to take care of themselves and survive on their own after they become adults, so pregnant women must take it seriously. Are you sending information first if you have passed the non-invasive test? 2

Non-invasive DNA prenatal testing

Non-invasive DNA, that is, non-invasive genetic testing, non-invasive DNA prenatal testing, also known as non-invasive prenatal DNA testing (Noninvasive Prenatal Testing, NIPT), non-invasive fetal chromosomal aneuploidy testing, etc. The most widely used technique name internationally is NIPT, as defined by the Committee of the American College of Obstetricians and Gynecologists.

Limited by the level of technological development, currently domestic non-invasive DNA mainly screens for three common chromosomal diseases, namely T21 chromosomal abnormalities (Down syndrome), T18 chromosomal abnormalities (Edwards syndrome) and T13 chromosome abnormality (Patau syndrome).

According to the "Technical Specifications for High-Throughput Gene Sequencing Prenatal Screening and Diagnosis (Trial)" (hereinafter referred to as the "Specifications") issued by the National Health and Family Planning Commission, non-invasive DNA uses gene sequencing technology A method of prenatal screening and diagnosis that only requires collecting more than 5 ml of peripheral venous blood from pregnant women to extract fetal cell-free DNA fragments contained in maternal peripheral plasma. Through next-generation high-throughput DNA sequencing and bioinformatics analysis, The genetic information of the fetus can be known and the risk of the fetus suffering from chromosomal aneuploidy diseases can be detected.

The regulations clearly stipulate that non-invasive DNA prenatal testing is suitable for three main categories of pregnant women:

1. In the prenatal screening report, 1/1000≤ The risk rate test value of Down syndrome ≤ 1/270, the risk rate test value of 1/1000 ≤ 18-trisomy syndrome ≤ 1/350, and the risk rate test value of 1/1000 ≤ 13-trisomy syndrome ≤ 1/350, that is, serum Medical screening and imaging examinations show that common chromosomal aneuploidy is close to high risk.

2. Contraindications for interventional prenatal diagnosis such as threatened abortion, fever, bleeding tendency, and unresolved infection during pregnancy.

3. You are in a relatively advanced gestational age (more than 20 weeks and 6 days of pregnancy), and it is within the time when non-invasive DNA prenatal testing is available, and you have missed the best time for serological screening, or missed the test. The timing of prenatal diagnosis, but there are special requirements for reducing the risk of three major chromosomal diseases.

Compared with the applicable population, the effect of non-invasive DNA prenatal testing will be reduced to a certain extent for pregnant women who should be used with caution:

1. Prenatal screening is high-risk, and the age at the expected date of delivery is ≥35 years old. Pregnant women of advanced age, and other direct indications for prenatal diagnosis.

2. Pregnant with twins.

3. Gestational age: 100 kilograms.

5. Conceive through in vitro fertilization-embryo transfer (IVF-ET).

6. Suffering from combined malignant tumors.

Finally, there are four special categories of pregnant women who are not suitable for non-invasive DNA prenatal testing, including:

1. One of the couple has a clear chromosomal abnormality, and the pregnant woman has experienced chromosomal abnormalities Abnormal fetal delivery.

2. Pregnant women have received allogeneic blood transfusion, transplant surgery, cell therapy or immunotherapy within one year, which will interfere with the results of non-invasive DNA prenatal testing.

3. The results of fetal imaging screening such as B-ultrasound during pregnancy suspect that the fetus may have chromosomal abnormalities, such as microdeletion and microduplication syndrome.

4. High-risk groups for various genetic diseases. Should I send you the information first if you have passed the non-invasive test? 3

Non-invasive generally refers to non-invasive DNA prenatal testing. The results of non-invasive DNA prenatal testing do not come out as late as possible. There is no such saying.

Non-invasive DNA prenatal testing refers to the examination of chromosome number abnormalities. It uses second-generation sequencing technology of genetic testing and is usually done at more than 12 weeks. It is recommended that non-invasive DNA prenatal testing be performed as early as 12 weeks after the test, because it may take 2-3 weeks for the final value of the sequencing results to be available after the test.

Non-invasive DNA prenatal testing can be done during NT at 12 weeks of pregnancy. If the pregnancy is high risk, it is still time to make an appointment for amniocentesis. If it is done later, when the test results are abnormal, the later gestational age may affect further examination in the later period. Therefore, the non-invasive DNA prenatal test should be performed as early as possible, because if any problem is found, the pregnant woman will have to draw amniotic fluid. The time for drawing amniotic fluid cannot exceed 24 weeks, so try to perform non-invasive DNA prenatal testing as early as possible.

In addition, pregnant women must pay attention to regular pregnancy tests during pregnancy and seek medical treatment promptly if any abnormalities are found.

Non-invasive DNA prenatal testing technology

Non-invasive DNA prenatal testing, also known as non-invasive prenatal DNA testing, non-invasive fetal chromosomal aneuploidy testing wait.

According to the American College of Obstetricians and Gynecologists, an authoritative international academic organization, non-invasive prenatal DNA testing (Non-invasive Prenatal Testing) is the most widely used technology name.

Non-invasive DNA prenatal testing technology only requires the venous blood of pregnant women, uses next-generation DNA sequencing technology to sequence the cell-free DNA fragments (including fetal cell-free DNA) in maternal peripheral plasma, and performs biological analysis on the sequencing results. Information analysis can obtain the genetic information of the fetus to detect whether the fetus suffers from the three major chromosomal diseases.

Maternal plasma contains fetal cell-free DNA, providing a realistic basis for this project. Fetal chromosomal abnormalities will bring about slight changes in maternal DNA content. This change can be detected through deep sequencing and biological information analysis, providing a theoretical basis for the project.